None of the McMaster-affiliated researchers who supported the guideline development process had any current, material interest in a commercial entity with any product that could be affected by the guidelines. On a recommendation-by-recommendation basis, none of the researchers who contributed to the systematic evidence reviews informing a recommendation had any current, material interest in a commercial entity with any product that could be affected by the recommendation. Supplement 3 provides the 27 NOVEMBER 2018 x VOLUME 2, NUMBER 22 ASH 2018 VTE GUIDELINES: ANTICOAGULATION MANAGEMENT 3261 complete disclosure of interest forms of researchers who contrib- uted to these guidelines. Formulating specific clinical questions and determining outcomes of interest The panel used the GRADEpro Guideline Development Tool (www. and SurveyMonkey (www.surveymonkey.com) to brainstorm and then prioritize the questions described in Table 1. The panel selected outcomes of interest for each question a priori, following the approach described in detail elsewhere.22 In brief, the panel brainstormed all possible outcomes and then rated their relative importance for decision-making following the GRADE During this rating process, the panel used definitions of the outcomes ( marker states ) developed for these guidelines. Rating outcomes by their relative importance helps focus attention on those outcomes that are most important and helps resolve or clarify potential disagreements. The panel rated the following outcomes as critical for decision-making across questions: mortality, PE, DVT in the upper leg, DVT in the upper arm, and major bleeding. For specific questions, other outcomes were included to inform decision-making, including TTR as a surrogate for bleeding and thrombosis, impairment of quality of life, critical INR as a surrogate for bleeding and thrombosis, increased duration of hospitalization, medication adherence as a surrogate for bleeding and thrombosis, and delay of intervention. 